Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Marszalkowska 24, 00-576 Warsaw, Poland.
Respir Physiol Neurobiol. 2013 Jun 1;187(1):64-7. doi: 10.1016/j.resp.2013.03.013. Epub 2013 Mar 30.
Cardiotoxicity is a well known consequence of cancer chemotherapy. Cisplatin-based combinations are standard regimens in the therapy of advanced non-small cell lung cancer. Administration of cisplatin-containing chemotherapy causes significant oxidative and nitrosative stress in some patients. Cardiac blood biomarkers can be used to evaluate cardiac status, may help to identify patients at risk myocardial damage evaluation and are able to detect subclinical, early-stage cisplatin-induced cardiotoxicity. The relevance of cardiovascular complications in cancer patients and identification of individual risk factors for developing cardiovascular toxicity merit further evaluation and a longer follow-up is needed.
心脏毒性是癌症化疗的已知后果。顺铂为基础的联合化疗方案是治疗晚期非小细胞肺癌的标准方案。顺铂化疗会导致部分患者产生显著的氧化应激和硝化应激。心脏血液生物标志物可用于评估心脏状态，有助于识别有心肌损伤风险的患者，并能检测出亚临床、早期顺铂诱导的心脏毒性。有必要进一步评估癌症患者心血管并发症的相关性以及确定发生心血管毒性的个体危险因素，并需要进行更长时间的随访。
